We actively engage in impactful, science-driven, non-competitive Public-Private Partnerships together with industry, academia and other public partners.

Using new technology, data, and tools, we build a better knowledge of disease and treatment areas. Together with our partners, we help improve healthcare systems for the benefit of patients and society.

On this page you can see more about our current partnerships and find out how you can connect with us to drive innovation and change. 

Follow the below links and learn how to get involved with us – and other dedicated partners – in some of the major Public-Private Partnership frameworks:

IMI – Innovative Medicines Initiative

IHI – Innovative Health Initiative

AMP – Accelerating Medicines Partnership


Novo Nordisk is an active participant in the EU-anchored Innovative Health Initiative (IHI), formerly the Innovative Medicines Initiative (IMI) – the world’s largest Public-Private Partnership framework within health technology and life sciences.

For more than 10 years, Novo Nordisk has been a significant IHI contributor with direct involvement in over 40 diverse stakeholder projects, each with multi-million Euro budgets.

“We are very happy to have joined the IMI SOPHIA and work in partnership with Novo Nordisk. This fruitful collaboration offered the possibility for the Medical Informatics Platform, which currently serves multinational consortia to explore decentralised medical data in the field of brain diseases, to extend to the field of obesity.”

- From Prof. Philippe Ryvlin, Head of The Department of Clinical Neurosciences (DNC) at the Lausanne University Hospital (CHUV)


Having a “hypo” – or experiencing hypoglycemia – is a common problem and fear for people living with diabetes. In plain words, it means that one’s blood sugar level drops too low. If not treated correctly and swiftly, this can be a very dangerous condition. A severe “hypo” incident can ultimately provoke loss of consciousness and even death.

Hypo-RESOLVE aims to uncover the mechanism of hypoglycemia and its physical, psychological, and economic consequences.

The Hypo-RESOLVE project is the first Public-Private Partnership led by Novo Nordisk in the diabetes disease area. The project is an international consortium of 23 partners with experts from academia, industry and society. The consortium partners include Stichting Radboud Universitair Medisch Centrum, Eli Lilly and Medtronic, among others. The estimated budget is €26.8 million.

The aim of the project is to pave the way for new, better treatments for people with diabetes that will help them maintain healthy blood sugar levels.

The project started 01/05/2018 and will end 31/10/2023

Visit the Hypo-RESOLVE project homepage here: https://hypo-resolve.eu/

Click here to get an overview of the partners: The network | Hypo-RESOLVE

HYPO-Resolve Logo

The mission of the SOPHIA project (Stratification of Obesity Phenotypes to Optimize Future Therapy) is to identify ways of predicting complications of obesity – and predict which patient groups best respond to specific treatments.

The SOPHIA project has an international consortium of 36 partners comprised of experts from academia, industry and society. The consortium partners include Eli Lilly, University College Dublin and Obesity Action Coalition, among others.

The project aims to build a federated database that is used to identify and chart models for sustainable treatment pathways that will be valuable for patients, healthcare systems, researchers and clinicians. SOPHIA works towards providing a better understanding of this complex and chronic disease and creating a shared narrative surrounding obesity. The estimated budget is €16.5 million.

The project started on 01/06/2020 and will end 31/05/2025.

Visit the IMI-project homepage here: SOPHIA | IMI Innovative Medicines Initiative (europa.eu) or IMI SOPHIA’s own website here: https://imisophia.eu/


SOPHIA project logo

The burden of cardiovascular disease (CVD) on society is huge with >85 million people affected in Europe. The overall prevalence continues to grow due to lifestyles and population aging. Heart failure (HF) is the final common pathway of all CVD and has a 5-year mortality rate of 20-50% despite significant advances in therapy.

ICARE4CVD aims to address this burden by contributing to three essential steps to improve the current care pathways, covering all stages from early risk to established HF: 1) early diagnosis to identify patients at risk of CVD and divide them into clinically meaningful subgroups; 2) risk stratification for these subgroups to define the urgency for intervention; and 3) prediction of treatment response for each subgroup.

The iCARE4CVD project has an international consortium of 33 partners comprised of experts from academia, pharmaceuticals and MedTech. The budget is €23 million with a start date of October 2023 lasting for 4 and a half years.

Visit the iCARE4CVD project homepage  here